Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly

Acromegaly Clinical Trial

— DOPAACRO 002  

Official title:

A Phase IIa, Open-label, Single-arm, Two Stage, Multi-centre Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Repeated Subcutaneous Administration of BIM23B065 in Subjects With Acromegaly

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03045302
• Other study ID #: D-FR-10380-002
• Secondary ID: 2015-003868-37
• Status: Terminated
• Phase: Phase 2
• Start date: January 26, 2017
• Est. completion date: June 2, 2017

Study information

• Verified date: March 2019
• Source: Ipsen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the protocol is evaluate the safety, the pharmacodynamics and the pharmacokinetic of repeated administration of BIM23B065 in subjects with acromegaly.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: June 2, 2017
• Est. primary completion date: May 17, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Provided written informed consent prior to any study related procedures.

• Subjects will have a documented diagnosis of acromegaly.

• Subjects will have active acromegaly confirmed by a mean serum concentration of GH over 2 hours > 2.5 µg/L at screening analysed by central laboratory.

• Subjects who have had pituitary surgery must be >8 weeks post-surgery.

• 18 to 75 years of age.

• Negative pregnancy test (female subjects).

• Female who is either of non-childbearing potential or who is not pregnant at screening and agrees to use highly effective contraception during whole duration of the study. Non-childbearing potential is defined as being postmenopausal for at least 1 year, or women with documented infertility (natural or acquired).

• Male subjects must agree that, if their partner is at risk of becoming pregnant, they will use a medically accepted, effective method of contraception (i.e. condom) for the duration of the treatment period of the study.

Exclusion Criteria:

• The subject has received long-acting Somatostatin Analogues (SSA) within 12 weeks prior screening (e.g.octreotide long acting release (LAR), lanreotide Autogel, pasireotide LAR).

• The subject has received short-acting SSA within 1 week (e.g. octreotide SC) prior to screening.

• The subject has received a dopamine agonist within 6 weeks (e.g., bromocriptine or cabergoline) prior to screening.

• The subject has received GH antagonist within 12 weeks prior to screening (e.g., pegvisomant).

• The subject had undergone radiotherapy to the pituitary gland at any time prior to study entry.

• It is anticipated that the subject will undergo pituitary surgery or radiation to the pituitary gland during the study, or will require additional medical therapy for acromegaly (including SSA, pegvisomant, or dopamine agonists) during the study.

• The subject has unsubstituted/untreated adrenal insufficiency.

• If the subject has any history of postural hypotension or evidence of postural hypotension at screening (>= 20 mm Hg decrease in Systolic blood pressure (SBP), >= 10 mm Hg decrease in diastolic blood pressure, or >=30 bpm increases in pulse rate, after standing for 2 minutes from resting supine position of at least 10 min).

• Subject with poorly controlled diabetes mellitus (presence of ketoacidosis or a glycosylated hemoglobin level >10%).

• Subject with diabetes treated with insulin for less than 6 weeks prior to study entry, or with an unstable insulin dose in the 6 weeks prior to study entry or HbA1c>10%.

• Subject is taking beta-blockers (which can inhibit compensatory increases in HR during hypotensive episodes).

• Subject is being treated for hypertension and in the opinion of the investigator their antihypertensive medication puts them at increased risk of postural hypotension.

• Subject is hypotensive at screening as defined as systolic < 90 mmHg and/or diastolic <60 mmHg.

• Subject has clinically significant hepatic abnormalities and/or alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) =2 x ULN and/or alkaline phosphatase (AP) =2 x ULN and/or total bilirubin =1.5 x ULN and gamma-glutamyl transferase (GGT) =2.5 x ULN during the Screening period (local laboratory results).

• Subject has a compression of the optic chiasm causing visual-field defects.

• Subject is receiving any oestrogen-containing Hormone Replacement Therapy (HRT).

• Subject has clinically significant pancreatic abnormalities and/or amylase and/or lipase =2 x ULN during the Screening period (local laboratory results).

• Any significant renal abnormalities, including confirmed proteinuria and/or creatinine =1.5x ULN during screening assessed by the local laboratory.

Related Conditions & MeSH terms

• Acromegaly

Intervention

Drug:
• BIM23B065
Subcutaneous twice a day or three times a day administration of BIM23B065. Dose will be 0.4, 0.6, 0.8 or 1 mg (twice a day or three times a day).

Locations

Country	Name	City	State
Belgium	CHU de Liège, University of Liège, Domaine Universitaire du Sart-Tilman	Liège
Hungary	Medical Centre, University of Pecs, I Department of Internal Medicine	Pecs
Serbia	Clinical Center of Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases	Belgrade
Ukraine	"Institute of Endocrinological Pathology named after Danilevskij V.Ya., AMS of Ukraine", Department of General Endocrinology	Kharkiv
Ukraine	"Institute of Endocrinology and Metabolism named after V.P.Komisarenko, AMS Ukraine", Department of General Endocrinology	Kiev
Ukraine	Vinnitsa Regional Endocrinology Dispensary, Vinnitsa National Medical University named after M.I Pirogov, Therapeutic Department ? 2	Vinnitsa

Sponsors (1)

Lead Sponsor	Collaborator
Ipsen

Countries where clinical trial is conducted

Belgium,  Hungary,  Serbia,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Number of Subjects Who Were Growth Hormone (GH) Responders at Day 14 of the Treatment Period	A GH responder was defined as a subject with mean serum GH concentration =2.5 micrograms per litre (mcg/L) or >50% reduction from mean baseline GH concentration after a 6-day titration and an 8-day treatment period with BIM23B065. The mean serum concentration of GH was measured over 6 hours at baseline (Day -1) and on Day 14. The number of subjects who were GH responders at Day 14 of the treatment period is presented.	From baseline (Day -1) to Day 14.